Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Mahmoud Youns
- Yu-Jie Fu
- Yuan-Gang Zu
- Anne Kramer
- V Badireenath Konkimalla
- Bernhard Radlwimmer
- Holger Sueltmann
- Thomas Efferth
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000281258900004&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1007/s00210-010-0541-6
- eISSN
- 1432-1912
- Externe Identifier
- Clarivate Analytics Document Solution ID: 642YW
- PubMed Identifier: 20668838
- ISSN
- 0028-1298
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Schlüsselwörter
- Chalcone flavonoid
- Chemotherapy
- Molecular pharmacology
- Natural products
- Pharmacogenomics
- Tumour genetics
- Paginierung
- 221 - 234
- Datum der Veröffentlichung
- 2010
- Status
- Published
- Titel
- Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics
- Sub types
- Article
- Ausgabe der Zeitschrift
- 382
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Autoren
- Mahmoud Youns
- Yu-Jie Fu
- Yuan-Gang Zu
- Anne Kramer
- V Badireenath Konkimalla
- Bernhard Radlwimmer
- Holger Sültmann
- Thomas Efferth
- DOI
- 10.1007/s00210-010-0541-6
- eISSN
- 1432-1912
- ISSN
- 0028-1298
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Sprache
- en
- Online publication date
- 2010
- Paginierung
- 221 - 234
- Datum der Veröffentlichung
- 2010
- Status
- Published
- Herausgeber
- Springer Science and Business Media LLC
- Herausgeber URL
- http://dx.doi.org/10.1007/s00210-010-0541-6
- Datum der Datenerfassung
- 2023
- Titel
- Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics
- Ausgabe der Zeitschrift
- 382
Data source: Crossref
- Abstract
- The development of drug resistance in cancer cells necessitates the identification of novel agents with improved activity towards cancer cells. In the present investigation, we compared the cytotoxicity of the chalcone flavonoide, isoliquiritigenin (ISL), with that of doxorubicin (DOX) and methotrexate (MTX) in five T cell acute lymphoblastic leukaemia (T-ALL) cell lines (Jurkat, J-Jhan, J16, HUT78 and Karpas 45). To gain insight into the molecular mechanisms which determine the response of T-ALL cells towards ISL, DOX and MTX, we applied array-based matrix comparative genomic hybridisation and microarray-based mRNA expression profiling and compared the genomic and transcriptomic profiles of the cell lines with their 50% inhibition (IC(50)) values for these three drugs. The IC(50) values for ISL did not correlate with those for DOX or MTX, indicating that ISL was still active in DOX- or MTX-unresponsive cell lines. Likewise, the genomic imbalances of chromosomal clones and mRNA expression profile significantly correlating with IC(50) values for ISL were different from thoses correlating with IC(50) values for DOX and MTX. In conclusion, ISL represents a cytotoxic natural product with activity towards T-ALL cell lines. There was no cross-resistance between ISL and DOX or MTX, and the genomic and transcriptomic profiles pointed to different molecular modes of action of ISL as compared to DOX and MTX, indicating that ISL may be a valuable adjunct for cancer therapy to treat otherwise drug-resistant tumours.
- Addresses
- Department of Pharmaceutical Biology, University of Mainz, Mainz, Germany.
- Autoren
- Mahmoud Youns
- Yu-Jie Fu
- Yuan-Gang Zu
- Anne Kramer
- V Badireenath Konkimalla
- Bernhard Radlwimmer
- Holger Sültmann
- Thomas Efferth
- Thomas Efferth
- DOI
- 10.1007/s00210-010-0541-6
- eISSN
- 1432-1912
- Externe Identifier
- PubMed Identifier: 20668838
- Open access
- false
- ISSN
- 0028-1298
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- Naunyn-Schmiedeberg's archives of pharmacology
- Schlüsselwörter
- Cell Line, Tumor
- Jurkat Cells
- Humans
- Leukemia, T-Cell
- Chalcones
- Methotrexate
- Doxorubicin
- RNA, Messenger
- Antineoplastic Agents
- Antimetabolites, Antineoplastic
- Microarray Analysis
- Gene Expression Profiling
- Inhibitory Concentration 50
- Pharmacogenetics
- Drug Resistance, Neoplasm
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2010
- Paginierung
- 221 - 234
- Datum der Veröffentlichung
- 2010
- Status
- Published
- Datum der Datenerfassung
- 2010
- Titel
- Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics.
- Sub types
- Comparative Study
- Research Support, Non-U.S. Gov't
- Journal Article
- Ausgabe der Zeitschrift
- 382
Data source: Europe PubMed Central
- Abstract
- The development of drug resistance in cancer cells necessitates the identification of novel agents with improved activity towards cancer cells. In the present investigation, we compared the cytotoxicity of the chalcone flavonoide, isoliquiritigenin (ISL), with that of doxorubicin (DOX) and methotrexate (MTX) in five T cell acute lymphoblastic leukaemia (T-ALL) cell lines (Jurkat, J-Jhan, J16, HUT78 and Karpas 45). To gain insight into the molecular mechanisms which determine the response of T-ALL cells towards ISL, DOX and MTX, we applied array-based matrix comparative genomic hybridisation and microarray-based mRNA expression profiling and compared the genomic and transcriptomic profiles of the cell lines with their 50% inhibition (IC(50)) values for these three drugs. The IC(50) values for ISL did not correlate with those for DOX or MTX, indicating that ISL was still active in DOX- or MTX-unresponsive cell lines. Likewise, the genomic imbalances of chromosomal clones and mRNA expression profile significantly correlating with IC(50) values for ISL were different from thoses correlating with IC(50) values for DOX and MTX. In conclusion, ISL represents a cytotoxic natural product with activity towards T-ALL cell lines. There was no cross-resistance between ISL and DOX or MTX, and the genomic and transcriptomic profiles pointed to different molecular modes of action of ISL as compared to DOX and MTX, indicating that ISL may be a valuable adjunct for cancer therapy to treat otherwise drug-resistant tumours.
- Date of acceptance
- 2010
- Autoren
- Mahmoud Youns
- Yu-Jie Fu
- Yuan-Gang Zu
- Anne Kramer
- V Badireenath Konkimalla
- Bernhard Radlwimmer
- Holger Sültmann
- Thomas Efferth
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/20668838
- DOI
- 10.1007/s00210-010-0541-6
- eISSN
- 1432-1912
- Ausgabe der Veröffentlichung
- 3
- Zeitschrift
- Naunyn Schmiedebergs Arch Pharmacol
- Schlüsselwörter
- Antimetabolites, Antineoplastic
- Antineoplastic Agents
- Cell Line, Tumor
- Chalcones
- Doxorubicin
- Drug Resistance, Neoplasm
- Gene Expression Profiling
- Humans
- Inhibitory Concentration 50
- Jurkat Cells
- Leukemia, T-Cell
- Methotrexate
- Microarray Analysis
- Pharmacogenetics
- RNA, Messenger
- Sprache
- eng
- Country
- Germany
- Paginierung
- 221 - 234
- Datum der Veröffentlichung
- 2010
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2010
- Titel
- Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics.
- Sub types
- Comparative Study
- Journal Article
- Research Support, Non-U.S. Gov't
- Ausgabe der Zeitschrift
- 382
Data source: PubMed
- Beziehungen:
- Property of